This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Concentration of donepezil to the cognitive response in Alzheimer disease


Yang, Yuan-Han, Chen, Chun-Hung, Chou, Mei-Chuan, Li, Chien-Hsun, Liu, Ching-Kuan, Chen, Su-Hwei


Journal Of Clinical Psychopharmacology, Volume: 33, No.: 3, Pages.: 351-355

Year of Publication



Background: Donepezil has been approved, and higher dosages are recommended for the treatment of Alzheimer disease (AD). However, a few studies have reported different cognitive responses in patients with AD treated with donepezil without measuring the concentration.; Methods: We evaluated the relationships between the therapeutic responses and plasma concentrations of donepezil in various cognitive domains using the Cognitive Ability Screening Instrument among 37 patients with newly diagnosed mild stage AD taking donepezil 5 mg/d.; Results: Among the 9 cognitive domains in the Cognitive Ability Screening Instrument, the long-term memory domain had the highest improvement ratio (81.1%) compared with the other domains. An increased donepezil plasma concentration [mean (SD), 75.14 (32.16) ng/mL] was significantly associated with the improvement of long-term memory (P = 0.045; odds ratio, 0.959; 95% confidence interval, 0.920-0.999) after adjusting for age, sex, education, and apolipoprotein E genotype.; Conclusions: Although there are some limitations in our study, these findings indicate that a higher concentration of donepezil improves long-term memory in patients with mild stage AD and imply the possible benefits in the advanced stage of AD for relatively preserved long-term memory.;

Bibtex Citation

@article{Yang_2013, doi = {10.1097/jcp.0b013e31828b5087}, url = {}, year = 2013, month = {jun}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {33}, number = {3}, pages = {351--355}, author = {Yuan-Han Yang and Chun-Hung Chen and Mei-Chuan Chou and Chien-Hsun Li and Ching-Kuan Liu and Su-Hwei Chen}, title = {Concentration of Donepezil to the Cognitive Response in Alzheimer Disease}, journal = {Journal of Clinical Psychopharmacology} }


aged, aged, 80 and over, alzheimer disease, cognition, donepezil, drug effects, drug therapy, female, humans, indans, male, nootropic agents, pharmacokinetics, physiopathology, piperidines, prospective studies, severity of illness index, therapeutic use, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime